Beyond Degradation: Cell-based and Biophysical PROTAC Characterisation using BRD4 as a Target
On-demand Webinar
Beyond Degradation: Cell-based and Biophysical PROTAC Characterisation using BRD4 as a Target
During PROTAC development various assays are required to inform and progress the design-make-test cycle. PROTAC’s have been developed to BRD4 – a member of the BET (bromodomain and extra-terminal) family.
At Charnwood Molecular we have used cell-based and biophysical techniques to investigate the BRD4-targeting PROTAC ‘dBET6’ to elucidate a binding mechanism, confirm proteasomal degradation and monitor its impact on cellular behaviour.
In this webinar we demonstrate a set of orthogonal techniques used to probe BRD4 PROTAC activity that we might typically implement in a PROTAC development cascade to build confidence in target depletion and associated biological validation.
Date & time
The webinar took place on Tuesday 13 December 2022
Duration
The webinar is scheduled for an hour and will include a Q&A session at the end.
An on-demand recording is now available, simply complete the form below for a link to the recording.
Presenters
Dr Gary Allenby has over 30 years of pre-clinical drug discovery expertise initially in large pharma (Hoffmann La Roche, GSK and AstraZeneca) and more recently in the CRO sector. Gary co-founded Aurelia Bioscience prior to its acquisition by Charnwood Molecular. Gary offers expertise in targeted protein degradation, bioassay development and automating cell-based assays for high throughput screening across a range of therapeutic areas and targets.
Now with a group of 20 Ph.D. drug discovery scientists, his focus is on the development of drug discovery screening cascades for clients, in addition to the development and implementation of new and advanced technologies for the study of biology and their application to client projects.
Dr James Chamberlain achieved a distinction in his clinical microbiology Masters, before gaining a PhD in molecular cell biology – both from the University of Nottingham. After time as a research fellow James has spent over three years in an industrial CRO environment and specialises in live-cell imaging, investigating changes in cell behavior to inform discovery cascades.”
Find out more about our PROTAC research experience here.